- Investing Ideas
- U.K. Pharmaceuticals & Biotech Healthy potentially undervalued
U.K. Pharmaceuticals & Biotech Healthy potentially undervalued
Results
6
Companies which are potentially undervalued and in an acceptable financial position.
6 companies
Diaceutics
Market Cap: UK£115.6m
A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.
DXRX
UK£1.44
7D
11.2%
1Y
7.5%
AstraZeneca
Market Cap: UK£197.3b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£126.32
7D
-0.3%
1Y
13.8%
GSK
Market Cap: UK£77.3b
Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK
UK£19.32
7D
0.6%
1Y
38.3%
Oxford Biomedica
Market Cap: UK£683.9m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£5.60
7D
-1.9%
1Y
20.6%
Hikma Pharmaceuticals
Market Cap: UK£3.3b
Develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.
HIK
UK£15.85
7D
0.2%
1Y
-18.3%
hVIVO
Market Cap: UK£53.2m
Operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America.
HVO
UK£0.074
7D
-1.3%
1Y
-26.0%